Sign in

BLTE on Nasdaq

BELITE BIO, INC

BELITE BIO, INC is a pharmaceutical preparations company based in Grand Cayman, Cayman Islands.2 Its shares trade on Nasdaq under the symbol BLTE.2

Price unavailable

Last updated Oct 21, 2026.

Overview

-$77.6MNet income, fiscal 20253

Compare with another stock.

  • TickerBLTE on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersGrand Cayman, Cayman Islands2
  • Incorporated inCayman Islands4
  • Business address12750 High Bluff Drive Suite 475, San Diego, Ca 921304
  • Filer categoryLarge accelerated filer4
  • Legal formexempt company2
  • LEI984500BD54036BOEAE792
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressUgland House, KY1-1104 Grand Cayman, Cayman Islands2
  • Registered withGeneral Registry, 3350192

See how the biggest companies compare on our leaderboards

Belite Bio, Inc was incorporated in the Cayman Islands on March 27, 2018 as an exempted company with limited liability. Our legal name is Belite Bio, Inc and our commercial name is Belite Bio. We are engaged in research and development of novel therapeutics targeting significant unmet needs. The address of our registered office in Cayman Islands is located at the Office of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. Our principal executive offices are located at 12750 High Bluff Drive Suite 475, San Diego, CA 92130. Our telephone number at that address is +1-858-246-6240. Puglisi & Associates, or Puglisi, serves as our agent for service of process in the United States. Puglisi’s address is 850 Library Avenue, Suite 204, Newark, Delaware 19711.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-10.1%Return on equity3
-$37.1MFree cash flow3

Financial statements

Operating income6783-$84.2M in 2025+1366% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$5.7M-$5.7M20202021: -$9.8M-$9.8M2021+71%2022: -$12.8M-$12.8M2022+31%2023: -$31.7M-$31.7M2023+147%2024: -$40.0M-$40.0M2024+26%2025: -$84.2M-$84.2M2025+111%
Net income6783-$77.6M in 2025+1249% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$5.8M-$5.8M20202021: -$9.7M-$9.7M2021+68%2022: -$12.6M-$12.6M2022+31%2023: -$31.6M-$31.6M2023+150%2024: -$36.1M-$36.1M2024+14%2025: -$77.6M-$77.6M2025+115%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Research and development$45.4M$29.9M$24.8M
Selling, general and administrative$38.8M$10.1M$6.8M
Total operating expenses$84.2M$40.0M$31.7M
Loss from operations-$84.2M-$40.0M-$31.7M
Interest income$6.6M$3.7M$74.0K
Interest expense-$2.0K-$20.0K-$25.0K
Other income (expense)-$41.0K$141.0K-$4.0K
Total other income, net$6.6M$3.9M$45.0K
Loss before income tax-$77.6M-$36.1M-$31.6M
Income tax expense$0$6.0K$9.0K
Net loss-$77.6M-$36.1M-$31.6M
Foreign currency translation adjustments, net of nil tax$124.0K-$286.0K$18.0K
Total comprehensive loss-$77.5M-$36.4M-$31.6M
Basic (in shares)33.5M shares30.5M shares26.6M shares
Diluted (in shares)33.5M shares30.5M shares26.6M shares
Basic (in dollar per share)-$2.31-$1.18-$1.19
Diluted (in dollar per share)-$2.31-$1.18-$1.19
Foreign currency translation adjustments tax$0$0$0

Compare BELITE BIO, INC with another company

Corporate structure

BELITE BIO, INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BELITE BIO, INC

  • Yu-Hsin Lin Filed SCHEDULE 13G/A on BELITE BIO, INC, latest May 14, 2026 (4 filings since Feb 15, 2023)
  • Darwin Global Management, Ltd. Filed SCHEDULE 13G/A on BELITE BIO, INC, latest Feb 17, 2026 (2 filings since Dec 10, 2025)
  • Lin Bioscience International Ltd. Filed SCHEDULE 13G on BELITE BIO, INC, latest Jan 21, 2025 (3 filings since Feb 14, 2023)
  • BELITE BIO, INC Grand Cayman, Cayman Islands

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BELITE BIO, INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$507.0K3 Dec 31, 2025$341.0K3 Dec 31, 2024+48.7%
Property and equipment, net$344.0K3 Dec 31, 2025$444.0K3 Dec 31, 2024−22.5%
Operating-lease assets (leased space)$433.0K3 Dec 31, 2025$521.0K3 Dec 31, 2024−16.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$352.9M3 Dec 31, 2025$31.7M3 Dec 31, 2024+1014.2%
Marketable securities, current$4.5M3 Dec 31, 2024

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$19.0K3 Dec 31, 2025$31.0K3 Dec 31, 2024−38.7%

Leadership

Who has led BELITE BIO, INC, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Hao-Yuan Chuang2026–now
Board members and other officers (6)

Timeline

  1. Oct 8, 2018Founded BELITE BIO, INC is founded2

Calendar

Coming up

  1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.65) a share, on Nov 10, 2025.15

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

210 filings to the SEC since October 2021: 4 annual reports, 43 insider forms, 9 large holders, 154 other. The latest 20:

  1. Oct 5, 20264 EDGAR
  2. Oct 1, 2026144 EDGAR
  3. Sep 9, 20264 EDGAR
  4. Sep 9, 20264 EDGAR
  5. Sep 8, 20266-K EDGAR
  6. Aug 14, 20264 EDGAR
  7. Aug 14, 20264 EDGAR
  8. Aug 13, 20266-K EDGAR
  9. Aug 12, 2026144 EDGAR
  10. Aug 12, 2026144 EDGAR
  11. Aug 11, 20266-K EDGAR
  12. Jun 22, 20264 EDGAR
  13. Jun 18, 2026144 EDGAR
  14. Jun 17, 20264 EDGAR
  15. Jun 16, 2026144 EDGAR
  16. Jun 15, 20266-K EDGAR
  17. May 20, 20266-K EDGAR
  18. May 14, 2026SCHEDULE 13G/A EDGAR
  19. May 8, 20264 EDGAR
  20. May 7, 20264 EDGAR

The 210 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

28 open-market trades by officers, directors and large owners since October 2021: 0 buys and 28 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 8, 2026Lin Yu-HsinChief Executive OfficerSale26,000$196.56$5.1MForm 4
Sep 8, 2026Chuang Hao-YuanChief Financial OfficerSale17,962$196.42$3.5MForm 4
Sep 4, 2026Lin Yu-HsinChief Executive OfficerSale74,435$187.71$14.0MForm 4
Sep 4, 2026Chuang Hao-YuanChief Financial OfficerSale49,433$187.63$9.3MForm 4
Aug 12, 2026Chuang Hao-YuanChief Financial OfficerSale367$180.35$66.2KForm 4
Aug 12, 2026Lin Yu-HsinChief Executive OfficerSale365$180.35$65.8KForm 4
Jun 18, 2026Scholl Hendrik PeterChief Medical OfficerSale10,000$145.24$1.5MForm 4
Jun 16, 2026Scholl Hendrik PeterChief Medical OfficerSale10,000$140.57$1.4MForm 4
May 7, 2026MATA NATHAN L.Chief Scientific OfficerSale666$153.21$102.0KForm 4
May 6, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$153.84$153.8KForm 4
May 5, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$155.50$155.5KForm 4
May 4, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$155.64$155.6KForm 4
May 1, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$155.78$155.8KForm 4
Apr 30, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$156.97$157.0KForm 4
Apr 29, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$155.82$155.8KForm 4
Apr 28, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$159.16$159.2KForm 4
Apr 27, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$162.64$162.6KForm 4
Apr 24, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$159.56$159.6KForm 4
Apr 23, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$166.28$166.3KForm 4
Apr 22, 2026MATA NATHAN L.Chief Scientific OfficerSale1,000$170.39$170.4KForm 4

All 28 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 81. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Darwin Global Management, Ltd.3,077,219$456.6M12.1%+19,807
Paradigm Biocapital Advisors LP1,232,877$189.8M3.6%+118,093
Rtw Investments, LP715,332$110.2M0.9%No change
Millennium Management LLC494,564$76.2M0.1%−75,524
Maverick Capital Ltd396,311$61.0M0.6%New
Eventide Asset Management, LLC390,829$60.2M0.8%+33,179
Deerfield Management Company, L.P.357,199$55.0M0.7%+53,186
Holocene Advisors, LP251,035$38.7M0.1%−243,460
Logos Global Management LP250,000$38.5M1.7%New
Morgan Stanley235,071$36.2M0.0%+33,662
UBS Group AG224,989$34.6M0.0%−543,370
Citadel Advisors LLC186,168$28.7M0.0%+184,160
Goldman Sachs Group Inc166,188$25.6M0.0%+60,679
Affinity Asset Advisors, LLC165,000$25.4M1.3%+100,000
Mpm Bioimpact LLC137,208$21.1M1.3%+49,163
Bank Of America Corp /de/124,783$19.2M0.0%+121,005
Patient Square Capital LP110,000$16.9M2.6%−6,684
Jane Street Group, LLC65,801$10.1M0.0%+53,579
Bnp Paribas Financial Markets57,125$8.8M0.0%+24,600
Renaissance Technologies LLC55,763$8.6M0.0%+3,763
Point72 Asset Management, L.P.51,186$7.9M0.0%New
Soleus Capital Management, L.P.50,524$7.8M0.3%New
Trexquant Investment LP49,516$7.6M0.0%+34,444
Two Sigma Investments, LP38,100$5.9M0.0%New
PFM Health Sciences, LP34,803$5.4M0.5%−24,629

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How BELITE BIO, INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBELITE BIO, INC1
  • CIK0001889109
  • Filer statusLarge accelerated filer not an emerging growth company; not a shell company5
  • Incorporated inCayman Islands5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address12750 High Bluff Drive Suite 475, San Diego, CA 921301
  • Phone858-246-62401
  • Shares outstanding39,339,960 shares as of Dec 31, 20255
  • AuditorDeloitte & Touche, Taipei, Taiwan PCAOB ID 5395; it also attests to the company’s internal control over financial reporting5
  • On EDGAR sinceDec 1, 20211
  • Filings210 in all: 6-K (55), 144 (43), 4 (34), 3 (9), 424B5 (8), CORRESP (7), UPLOAD (6), S-8 (5)1
    All 28 form types

    20-F (4), EFFECT (4), SC 13G (4), DRSLTR (3), F-1/A (3), SCHEDULE 13G (3), SEC STAFF LETTER (3), 144/A (2), DRS/A (2), F-3 (2), F-3ASR (2), FWP (2), SCHEDULE 13G/A (2), 424B4 (1), 424B7 (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-6 (1)

  • Latest filingsAnnual report (20-F) Mar 31, 2026

Securities registered for trading

ClassSymbolExchange
American depositary shares, each representing one ordinary shareBLTENasdaq Stock Market LLC
Ordinary shares, par value US$0.0001 per shareNasdaq Stock Market LLC

From the cover page of the 20-F filed Mar 31, 2026 (Section 12(b) of the Exchange Act).5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18